Cagent Vascular Introduces New Balloon Catheter

Cagent Vascular Inc. has launched its newest product, Serranator SL-PRO PTA Serration Balloon Catheter, a product built for pedal intervention and challenging-to-cross tibial disease.

Serranator SL-PRO uses Cagent’s proven Serration Technology on a redesigned platform offering improved deliverability and trackability,¹ while offering Serranator’s proven 1,000-fold increase in point force versus plain balloon. Moreover, its mechanism of action allows for predictable and controlled lumen gain with minimal dissection.

“As an experienced Serranator operator, my team has grown accustomed to the benefits of Serration including great lumen gain, low complication rate, and low 6% BTK vessel recoil vs. 55% measured recoil with Plain Balloon,”² Dr. Michael Lichtenberg, chief medical officer and director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany, said. “We also appreciate Serranator’s ability to safely and effectively treat complex disease, even down into the pedal arteries. With SL-PRO, we’re eager to experience the advantages of Serranation in this new, more deliverable platform.”

The Serranator and Serranator SL-PRO PTA Serration Balloon Catheters are U.S. Food and Drug Administration-cleared, novel balloons using proprietary stainless steel micro-serration technology that are designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies.

“We are committed to consistently developing and advancing solutions for physicians treating PAD patients, and winning the fight against this debilitating disease,” Cagent Vascular Chairman/CEO Brian Walsh stated. “With over 20,000 Serranation procedures now completed and a growing library of clinical data, Serranator has proven itself to be a valuable tool in this fight. The Serranator SL-PRO is a purpose-built tool for pedal intervention, and with it, the Serranator product family can now treat from hip to toe.”

Founded and led by serial medical technology entrepreneurs, Cagent Vascular develops serration technology to treat peripheral artery disease. The company has created a transformative improvement to conventional angioplasty, which is the most commonly performed procedure to restore blood flow. Although angioplasty has been used clinically for more than 50 years, there remains significant opportunities to optimize the therapy and to improve the treatment outcomes of cardiovascular disease.

References
¹ TD-0761 Serranator SL-PRO Independent Product Performance Report.
² Fereydooni A, Chandra V, Schneider PA, Giasolli R, Lichtenberg M, Stahlhoff S. Serration Angioplasty Is Associated With Less Recoil in Infrapopliteal Arteries Compared With Plain Balloon Angioplasty. J Endovasc Ther. 2023 Dec 7:15266028231215284.